Article
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Nature - 30 Mar 2017
Wylie Andrew A, Schoepfer Joseph, Jahnke Wolfgang, Cowan-Jacob Sandra W, Loo Alice, Furet Pascal, Marzinzik Andreas L, Pelle Xavier, Donovan Jerry, Zhu Wenjing, Buonamici Silvia, Hassan A Quamrul, Lombardo Franco, Iyer Varsha, Palmer Michael, Berellini Giuliano, Dodd Stephanie, Thohan Sanjeev, Bitter Hans, Branford Susan, Ross David M, Hughes Timothy P, Petruzzelli Lilli, Vanasse K Gary, Warmuth Markus, Hofmann Francesco, Keen Nicholas J, Sellers William R
Abstract excerpt
Chronic myeloid leukaemia (CML) is driven by the activity of the BCR-ABL1 fusion oncoprotein. ABL1 kinase inhibitors have improved the clinical outcomes for patients with CML, with over 80% of patients treated with imatinib surviving for more than 10 years. Second-generation ABL1 kinase inhibitors induce more potent molecular responses in both previously untreated and imatinib-resistant patients with CML. Studies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.